EN |  中文
Current Location:Home / Scientists&Research / Core Facilities / Text

Biologics Research Center&AntibodyCenter

Biologics Research Center & Antibody Center

Jianhua Sui, Ph.D.
Director of Biologics Research Center & Antibody Center, NIBS, Beijing, China
Phone: 86-10-80726688-8630
Fax: 86-10-80726021
E-mail: suijianhua@nibs.ac.cn

Research Description

The Biologics Research Center at NIBS is a research-oriented center established in 2012. We conduct human antibody related researches at the intersection of biology and medicine; we take interdisciplinary approaches to develop innovative biologics for diseases prevention and therapy. The center mainly focuses on infectious diseases, autoimmune diseases and cancer. Research programs include: 1) identification and validation of novel therapeutic targets; 2) development of therapeutic human monoclonal antibodies; 3) develop new antibody engineering technologies; 4) biologics production and pre-clinical validation of new antibody drugs, etc.

Selected Publications

1. Sui J, Sheehan J, Hwang WC, Bankston LA, Burchett SK, Huang CY, Liddington RC, Beigel JH, Marasco WA. Wide Prevalence of Heterosubtypic Broadly Neutralizing Human Anti-Influenza A Antibodies. Clin Infect Dis 2011; 52 (8):1003-1009

Comment in Clin Infect Dis: Donis R, and Cox N. Prospecting the Influenza Hemagglutinin to Develop Universal Vaccines, Clin Infect Dis (Editorial commentary) 2011, 52: 1010-1012.

2. Sui J* (*co-corresponding author), Hwang WC, Perez S, Wei G, Aird D, Chen L, Santelli E, Stec B, Cadwell G, Ali M, Murakami A, Yammanuru A, Han T, Cox N, Bankston LA, Donis RO, Liddington RC and Marasco WA. Structural and Functional Basis for Broad-Spectrum Neutralization of Avian and Human Influenza A Viruses. Nat Struct Mol Bio 2009, 16(3):265-73.

Commented in Nat Biotech, Nat Struct Mol Bio and Nat Med:

· Wang TT, Palese P. Universal epitopes of inflenza virus hemagglutinins? Nat Struct Mol Biol (News and Views), 2009,16 (3):233-4.

· Chen, GL, Subbarao K. Attacking the flu: Neutralizing antibdoies may lead to 'universal' vaccine. Nat Med (Between Bedside and Bench), 2009, 15: 1251-1252

· Influenza's Achilles' heel? Nat Biotech (Research highlights), 2009, 27 (14): 348

3. Sui J*(* co-corresponding author), Aird DR, Tamin A, Murakami A, Yan M, Yammanur, A, Jing H, Kan B, Liu, X, Zhu Q, Yuan Q, Adams GP, Bellini WJ, Xu J, Anderson LJ and Marasco WA. Broadening of Neutralization Activity to Directly Block a Dominant Antibody-Driven SARS-Coronavirus Evolution Pathway. Plos Pathogen 2008, 4(11):e1000197

4. Sui J. Li W, Roberts A, Matthews LJ, Murakami A, Vogel L, Wong SK, Subbarao K, Farzan M Marasco WA. Evaluation of human mab 80r for immunoprophylaxis of SARS by an animal study, epitope mapping and analysis of spike variants. J Virol 2005, 79(10):5900-5906

5. Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Moore MJ, Tallrico AS, Olurinde M, Choe H, Anderson LJ, Bellini WJ, Farzan M, and Marasco WA. Potent Neutralization of SARS Coronavirus Infection by a Human Monoclonal Antibody Against the ACE2-Binding Domain of Spike Protein.Proc Natl Acad Sci USA 2004,101(8):2536-41

6. Sui J, He Y, Jiang X, Dubel S, Han Z, Song Z. A single chain antibody obtained by cell panning of antibody phage inhibits homoaggregation of human leukemia cells. Hum Antibodies 2004;13(4):111-118

7. Sui J, Bai J, Tallarico A, Xu C and Marasco WA. Identification of CD4 and Transferrin Receptor Antibodies by Anti-CXCR4 Antibody Guided Pathfinder Selection. Eur J Biochem 2003; 270: 4497-4506

8. Sui J, Marasco WA. Evidence against Ebola virus sGP binding to human neutrophils by a specific receptor. Virology 2002, 303(1):9-14

9. DK Chang, Sui J, Geng S, Muvaffak A, Bai M, Fuhlbrigge R, Lo A, Yammanuru A, Hubbard L, Sheehan J, Campbell J, Zhu Q, Kupper T, Marasco WA. Humanization of an anti-CCR4 antibody that kills Cutaneous T Cell Lymphoma cells and abrogates suppression by T regulatory cells. Molecular Cancer Therapeutics 2012, accepted.

10. Xu C, Sui J, Tao H, Zhu Q, Wayne A. Marasco. Human anti-CXCR4 antibodies undergo VH replacement, exhibit functional V-Region sulfation and define CXCR4 antigenic heterogeneity. J Immunol 2007,179(4):2408-18

11. Li W, Sui J, Huang I-Cheuh, Kuhn JH, Radoshizky S, Marasco WA, Choe H, Farzan M. The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2.Virology 2007, 367(2):367-74

12. Hannah G, Sui J, Foellmer H, Wang T, Ledizet M, Murakami A, Noonan K, Lambeth C, Kar K, Anderson JF, Silva A, Koski R, Marasco WA, Fikrig E. Protection against West Nile virus with human single chain Fv-Fc fusion proteins that bind the viral envelop protein. J Virol 2005, 79:14606-4613

13. Bai J, Sui J, Demirjian A, Vollmer Jr CM, Marasco WA, Callery MP.Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in Vitro. Cancer Res 2005, 65(6):2344-2352

14. Tarnovitski N, Matthews LJ, Sui J, Gershoni JM Marasco WA. Mapping a neutralizing epitope on the SARS coronavirus spike protein: computational prediction based on affinity-selected peptides. J Mol Biol 2006, 359(1):190-201

15. Li W, Zhang C, Sui J, Kuhn JH, Moore MJ, Luo S, Wong SK, Huang IC, Xu K, Vasilieva N, Murakami A, He Y, Marasco WA, Guan Y, Choe H, Farzan M. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 2005, 24: 1634-1643

16. Hwang WC, Lin Y, Santelli E, Sui J, Jaroszewski L, Stec B, Farzan M, Marasco WA, Liddington RC. Structural basis of neutralization by a human anti-SARS Spike protein antibody, 80R. J Biol Chem 2006, 281(45):34610-6

17. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.Nature 2003, 426(6965):450-454

18. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng NY, Lee JH, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O'Donnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011, 208(1):181-93

Invited Reviews

1. Marasco WA, Sui J (*co-corresponding author). The growth and potential of human anti-viral monoclonal antibody therapeutics. Nature Biotechnology.2007, 25(12):1421-34. Invited review.

Book Chapters

1. Sui J, Marasco WA. Immunopathogenesis and Immunotherapy of SARS.  In: Chan Jane CK, Wong VCW Taam., editor. Challenges of Severe acute respiratory syndrome. HongKong: WB Saunders; 2006. p.139-160.

Patents

1. Marasco WA, Sui J., Anvir Y. Humanized Monoclonal Antibodies and Methods of Use. International Application No.: PCT/US2011/038970. Application date: June 03, 2011.

2. Marasco WA, Sui J, Liddington R. Conserved Hemagglutinin Epitopes, Antibodies To The Epitope And Methods Of Use. Publication No.WO/2010/027818. International Application No.: PCT/US2009/054950. Publication date: Nov. 03, 2010.

3. Marasco WA, Sui J, Zhu Q, Kupper T. Humanized Monoclonal Antibodies and Methods of Use. Publication No.: WO/2009/08651. International ApplicationNo.: PCT/US2008/088435. Publication date: Sept. 07, 2009

4. Marasco WA, Sui J. Antibodies against H5N1 and Methods of Use Thereof.Publication No.: WO/2009/079259. International Application No.: PCT/US2008/085876. Publication date: June 25, 2009.

5. Marasco WA, Sui J, Xu C. Antibodies against CXCR4 and Methods of Use Thereof. Publication No. WO/2006/08941. International Application No.: PCT /US2006/005691. Publication date: Aug. 24, 2006.

6. Fikrig E, Gould H, Koski RA, Ledizet M, Marasco WA, Sui J. Antibodies to West Nile Virus Polypeptides. Publication No. WO/2005/123774.International Application No.: PCT/US2005/022188. Publication date: Dec. 29, 2005.

7. Marasco WA, Sui J.  Antibodies Against SARS-CoV and Methods of Use Thereof. U.S. Patent No.7750,123. Patent expiration: Nov. 23, 2024